Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.

PURPOSE Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major bleeding among patients with venous thromboembolism in relation to both malignancy and the achieved INR. PATIENTS AND METHODS In a retrospective analysis, the INR-specific incidence of venous thromboembolic and major bleeding events during oral anticoagulant therapy was calculated separately for patients with and without malignancy. Eligible patients participated in two multicenter, randomized clinical trials on the initial treatment of venous thromboembolism. Patients were initially treated with heparin (standard or low-molecular weight). Treatment with vitamin K antagonists was started within 1 day and continued for 3 months, with a target INR of 2.0 to 3.0. RESULTS In 1,303 eligible patients (264 with malignancy), 35 recurrences and 12 bleeds occurred. Patients with malignancy, compared with nonmalignant patients, had a clinically and statistically significantly increased overall incidence of recurrence (27.1 v 9.0, respectively, per 100 patient-years) as well as bleeding (13.3 v 2.1, respectively, per 100 patient-years). In both groups of patients, the incidence of recurrence was lower when the INR was above 2.0 compared with below 2.0. CONCLUSION Although adequately dosed vitamin K antagonists are effective in patients with malignant disease, the incidence of thrombotic and bleeding complications remains higher than in patients without malignancy.

[1]  L. Heilmann,et al.  Hemorheologic variables in breast cancer patients at the time of diagnosis and during treatment , 1988, Cancer.

[2]  J. Jansson,et al.  Haemorrhagic and thromboembolic complications versus intensity of treatment of venous thromboembolism with oral anticoagulants. , 2009, Acta medica Scandinavica.

[3]  M. Prins,et al.  Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. , 1997, The New England journal of medicine.

[4]  M. Levine.  Treatment of thrombotic disorders in cancer patients. , 1997, Haemostasis.

[5]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[6]  J. Sixma,et al.  Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism , 1996, Thrombosis and Haemostasis.

[7]  J. Hirsh,et al.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. , 1996, The New England journal of medicine.

[8]  P. W. Willis,et al.  Hemorrhagic complications of anticoagulant therapy. , 1974, Archives of internal medicine.

[9]  P. Bossuyt,et al.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. , 1996, The New England journal of medicine.

[10]  D M Wallace,et al.  The Efficacy and Safety of Oral Anticoagulation in Patients with Cancer , 1995, Thrombosis and Haemostasis.

[11]  B. Gersh,et al.  Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. , 1995, Mayo Clinic proceedings.

[12]  J. Vandenbroucke,et al.  Assessment of a Bleeding Risk Index in Two Cohorts of Patients Treated with Oral Anticoagulants , 1996, Thrombosis and Haemostasis.

[13]  L. Schwartzberg,et al.  Hemorrhagic and thrombotic abnormalities of cancer. , 1988, Critical care clinics.

[14]  P. Prandoni.  Antithrombotic Strategies in Patients with Cancer , 1997, Thrombosis and Haemostasis.

[15]  F. Moore,et al.  Anticoagulants, venous thromboembolism, and the cancer patient. , 1981, Archives of surgery.

[16]  M. Liepman,et al.  Safety and efficacy of long‐term oral anticoagulation in cancer patients , 1987, Cancer.

[17]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[18]  E F Cook,et al.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. , 1987, The American journal of medicine.

[19]  D. Petitti,et al.  Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. , 1989, Journal of clinical epidemiology.